Treatment of recurrent ovarian cancer

Czech version

Authors: H. Robová; L. Rob; M. Pluta; M. Halaška jr.; R. Chmel
Authors‘ workplace: Praha, přednosta prof. MUDr. L. Rob, CSc. ; Gynekologicko porodnická klinika 2. LF UK a FN Motol
Published in: Ceska Gynekol 2009; 74(6): 464-468

Overview

Objective:
The description of current treatment possibilities in recurrent ovarian cancer.

Design:
Review article.

Setting:
Obstetrics and Gynecology Department, Charles University 2nd Medical Faculty and University Hospital Motol, Prague.

Methods:
The review of literature on treatment of recurrent ovarian cancer. Current data on chemotherapy, surgery and targeted biological therapy in recurrent ovarian cancer.

Conclusions:
Chemotherapy is indicated in most cases of recurrent ovarian cancer, surgery does not play an important role. Standard treatment of platinum-sensitive recurrent ovarian cancer is based on platinum combination chemotherapy. Standard treatment of platinum-refractory ovarian cancer represents non-platinum monotherapy. Targeted biological therapy should be still used only in the studies.

Key words:
recurrent ovarian cancer, platinum refractory ovarian cancer, platinum sensitive ovarian cancer.

Sources

1. Gordon, AN., Granai, CO., Rose, PO., et al. Phase II study of liposomal doxorubicin in platinum and paclitaxel refractory epithelial ovarian cancer. J Clin Oncol 2000,18, p. 3093-3100.

2. Markman, M., Kennedy, A., Webster, K., et al. Phase 2 trial of liposomal doxorubicin (40 mg/m 2 ) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000, 78, p. 369-372.

3. Muggia, FM., Hainsworth, JD., Jeffers, S., et al. Phase II study of liposomal doxorubicinin refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol, 1997, 15, p. 987-993.

4. Hoskins, P., Eisenhauer, E., Beare, S., et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998, 16, p. 2233-2237.

5. ten Bokkel Huining, W., Gore, M., Carmichael, J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol, 1997, 15, p. 2183-2193.

6. Whitney, AS., Leath, CA., Warner KH., et al. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol, 2007, 104, p. 591-595.

7. Eckhardt, S., Hernádi, Z., Thurzó, L., et al. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) study. Oncology, 1990, 47, p. 289-295.

8. Alici, S., Saip, P., Eralp, Y., et al. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am J Clin Oncol, 2003, 26, p. 358-362.

9. de Wit, R., van der Burg, M., Gaast, A., et al. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994, 5, p. 656-657.

10. Hoskins, PJ., Swenerton, KD. Oral etoposide in active against platinum-resistant epithelial ovarian cancer . J Clin Oncol, 1994, 12, p. 60-63.

11. Markman, M., Hakes, T., Reichman, B., et al. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol 1992, 119, p. 55-57.

12. Ferrandina, G., Ludovisi, M., Lorusso, D., et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008, 26, p. 890-896.

13. D’Agostino, G., Amant, F., Berteloot, P., et al. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003, 88, p. 266-269.

14. Mutch, DG., Orlando, M., Goss, T., et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007, 25, p. 2811-2818.

15. Bilgin, TOS., Yalcin, OT., Zorlu G., et al. Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. Eur J Gynecol Oncol 2003, 24, p. 169-170.

16. Friedlander, M., Milward, MJ., Bell, D., et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998, 9, p. 1343-1345.

17. Parmar, MK., Colombo, N., du Bois, A., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum–based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial. Lancet, 2003, 361, p. 2099-2106.

18. Pfisterer, J., Plante, M., Vergote I., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum–sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol 2006, 24, p. 4699-4707.

19. Alberts, DS., Liu, PY., Wilczynski, SP., et al. Randomized trial of pegylated liposomal dexorubicin (PLD) plus carboplatin versus carboplatin in platinum sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol, 2008, 108, p. 90-94.

20. Pujade-Lauraine, E., Mahner, S., Kaern, J., et al. A randomized phase III study of carboplatin and pegylated liposomal dexorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 2009, Suppl. 27, p. 799.

21. Burger, RA., Sill, MW., Monk, BJ., et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007, 25, p. 5165-5171.

22. Cannistra, SA., Matulonis, UA, Penson, RT., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25, p. 5180-5186.